We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

63 hedge funds and large institutions have $121M invested in Neos Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 12

37% more capital invested

Capital invested by funds: $88.5M → $121M (+$33M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less funds holding

Funds holding: 6763 (-4)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

28% less call options, than puts

Call options by funds: $466K | Put options by funds: $647K

Holders
63
Holders Change
-4
Holders Change %
-5.97%
% of All Funds
1.57%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
30
Reduced
12
Closed
14
Calls
$466K
Puts
$647K
Net Calls
-$181K
Net Calls Change
-$249K
Name Holding Trade Value Shares
Change
Change in
Stake
Nisa Investment Advisors
51
Nisa Investment Advisors
Missouri
$103K +$85.9K +11,300 New
Legal & General Group
52
Legal & General Group
United Kingdom
$53K +$10.3K +1,353 +30%
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
$30K +$17.6K +2,316 +252%
Bank of America
54
Bank of America
North Carolina
$20K +$9.35K +1,230 +122%
AG
55
Advisor Group
Arizona
$19K +$16K +2,100 New
CHP
56
Cable Hill Partners
Oregon
$14K +$7.6K +1,000 +176%
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$13.6K -$1.03K -136 -8%
TRCT
58
Tower Research Capital (TRC)
New York
$10K +$8.7K +1,145 New
AIP
59
Ameritas Investment Partners
Nebraska
$8K
QCG
60
Quadrant Capital Group
Ohio
$7K
CG
61
Cutler Group
California
$4K -$760 -100 -17%
Citigroup
62
Citigroup
New York
$1K -$3.53K -464 -86%
SCM
63
Stonepine Capital Management
Oregon
-$4.13M -565,100 Closed
PVI
64
Pura Vida Investments
New York
-$1.09M -150,000 Closed
MP
65
MSD Partners
New York
-$493K -67,600 Closed
EMG
66
Ellington Management Group
Connecticut
-$447K -61,200 Closed
CAM
67
Cormorant Asset Management
Massachusetts
-$369K -50,613 Closed
OM
68
Opaleye Management
Massachusetts
-$365K -50,000 Closed
HighTower Advisors
69
HighTower Advisors
Illinois
-$204K -28,000 Closed
Tudor Investment Corp
70
Tudor Investment Corp
Connecticut
-$146K -20,000 Closed
DTL
71
Dynamic Technology Lab
Singapore
-$118K -16,195 Closed
OAC
72
OMERS Administration Corp
Ontario, Canada
-$110K -15,100 Closed
TI
73
Trexquant Investment
Connecticut
-$85K -11,700 Closed
Creative Planning
74
Creative Planning
Kansas
-$37K -5,000 Closed
PAM
75
Panagora Asset Management
Massachusetts
-$10K -1,399 Closed

NEOS Hedge Fund Activity: Q3 2017 in Review

63 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2017, worth a combined $121M — up 37% from $88.5M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NEOS and 11 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 30 added.

The largest buyer was Cortina Asset Management, opening a new position worth an estimated $4.41M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $4.13M sold.

  • 63 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2017, down from 67 in Q2 2017.
  • Funds reported $121M of Neos Therapeutics, Inc stock for Q3 2017, up 37% quarter-over-quarter.
  • 11 funds opened new Neos Therapeutics, Inc positions in Q3 2017 and 14 closed out, a net change of -3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q3 2017 was Cortina Asset Management, an estimated $4.41M added.
  • The largest Neos Therapeutics, Inc seller in Q3 2017 was Stonepine Capital Management, an estimated $4.13M sold.

Based on aggregated 13F filings for Q3 2017.